Plasma protein oxidation and total antioxidant power in premenstrual syndrome

Asian Pacific Journal of Tropical Medicine

Volumn 3, Issue 3, 2010, Pages 237-240

  Tuladhar, Eans Tara ^a   Rao, Anjali ^a  

^a KASTURBA MEDICAL COLLEGE   (India)

Author keywords

Ferric reducing antioxidant power of plasma; Premenstrual tension; Protein carbonyl; Protein thiol

Indexed keywords

FERRIC REDUCING ANTIOXIDANT POWER OF PLASMA; PROTEIN CARBONYL; REACTIVE OXYGEN METABOLITE; THIOL; UNCLASSIFIED DRUG;

ADULT; ARTICLE; CARBONYL BLOOD LEVEL; CONTROLLED STUDY; FEMALE; FOLLICULAR PHASE; HUMAN; LUTEAL PHASE; MENORRHAGIA; OXIDATIVE STRESS; PREMENSTRUAL SYNDROME; PROTEIN BLOOD LEVEL; THIOL BLOOD LEVEL;

EID: 77950657801     PISSN: 19957645     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1995-7645(10)60017-X     Document Type: Article

References (39)

1. Billici M, Koroglu MA, Uydu HA Antioxidative enzyme activities and lipid peroxidation in major depression: Alteration by antidepressant treatments. J Affect Dis 2001, 64:43-51.
2. Vaddadi KS, Soosai E, Vaddadi G Low blood selenium concentration in schizophrenia patients on clozapine. Br J Clin Pharmacol 2003, 55:307-309.
3. Ranjekar PK, Hinge A, Hegde MV, Ghate M, Kale A, Sitasawad S, et al. Decreased antioxidant enzymes and membrane essential polyunsaturated fatty acids in schizophrenic and bipolar mood disorder patients. Psychiatry Res 2003, 121:109-122.
4. Datta K, Sinha S, Chattopadhyay P Reactive oxygen species in health and disease. Natl Med J India 2000, 13:304-310.
5. McCord JM The evolution of free radicals and oxidative stress. Am J Med 2000, 108:652-659.
6. Yonkers K, Davis LL Premenstrual dysphoric disorder. Comprehensive textbook of psychiatry 2000, 1952-1959. Lippincott Williams and Wilkins, Philadelphia. 7th ed. B.J. Sadock, V.A. Sadock (Eds.).
7. Steiner M, Born L Diagnosis and treatment of premenstrual dysphoric disorder: an update. Int Clin Psychopharmacol 2000, 15:S5-S17.
8. Bertone-Johnson ER, Hankinson SE, Johnson HR, Manson JE A simple method of assessing premenstrual syndrome in large prospective studies. J Reprod Med 2007, 52:779-786.
9. Pincus SM, Schmidt PJ, Palladino-Negro P, Rubinow DR Differentiation of women with premenstrual dysphoric disorder, recurrent brief depression and healthy controls by daily mood rating dynamics. J Psychiatr Res 2008, 42:337-347.
10. Kaur G, Gonsalves L, Thacker HL Premenstrual dysphoric disorder: a review for the treating practitioner. Cleve Clin J Med 2004, 71:303-318.
11. Hourani LL, Yuan H, Bray RM Psychosocial and lifestyle correlates of premenstrual symptoms among military women. J Womens Health (Larchmt) 2004, 13:812-821.
12. Wittchen HU, Becker E, Lieb R, Krause P Prevalence, incidence and stability of premenstrual dysphoric disorder in community. Psychol Med 2002, 32:119-132.
13. Kalia G, Sudheendran S, Rao A Antioxidant status and lipid peroxidation in premenstrual syndrome: a preliminary study. Clin Chem Acta 2001, 309:97-99.
14. Hu ML Measurement of protein thiol groups and glutathione in plasma. Methods Enzymol 1994, 233:380-385.
15. Motichnik PA, Frei B, Ames BN Measurement of antioxidants in human blood plasma. Methods Enzymol 1994, 234:269-279.
16. Grune T, Jung T, Merker K, Davies KJ Decreased proteolysis caused by protein aggregates, inclusion bodies, plaques, lipofuscin, ceroid, and 'aggresomes' during oxidative stress, aging, and disease. Int J Biochem Cell Biol 2004, 36:2519-2530.
17. Marnett LJ, Riggins JN, West JD Endogenous generation of reactive oxidants and electrophiles and their reaction with DNA and protein. J Clin Inv 2003, 111:583-593.
18. Benzie IFF, Strain JJ The ferric reducing ability of plasma (FRAP) as a measure of " Antioxidant Power": the FRAP assay. Anal Biochem 1996, 239:70-76.
19. Cao G, Prior RL Comparison of different analytical methods for assessing total antioxidant capacity of human serum. Clin Chem 1998, 44:1309-1315.
20. Benzie IFF, Strain JJ Ferric reducing /antioxidant power of biological fluids and modified version for simultaneous measurement of total antioxidant power and ascorbic acid concentration. Methods Enzymol 1999, 299:15-27.
21. Ling FW Recognizing and treating premenstrual dysphoric disorder in the obstetrics, gynecologic and primary care practices. J Clin Psychiatry 2000, 61(suppl):9-16.
22. Reznnick AZ, Packer L Oxidative Damage to proteins: spectrophotometric method for carbonyl assay. Methods Enzymol 1994, 233:357-363.
23. Mense SM, Remotti F, Bhan A, Singh B, El-Tamer M, Hei TK, et al. Estrogen-induced breast cancer: alterations in breast morphology and oxidative stress as a function of estrogen exposure. Toxicol Appl Pharmacol 2008, 232:78-85.
24. de Aguiar RB, Dickel OE, Cunha RW, Monserrat JM, Barros DM, Martinez PE Estradiol valerate and tibolone: effects upon brain oxidative stress and blood biochemistry during aging in female rats. Biogerontology 2008, 9:285-298.
25. Irwin RW, Yao J, Hamilton RT, Cadenas E, Brinton RD, Nilsen J Progesterone and estrogen regulate oxidative metabolism in brain mitochondria. Endocrinology 2008, 149:3167-3175.
26. Vedder H, Anthes N, Stumm G, Wurz C, Behl C, Kreig JC Estrogen hormones reduce lipid peroxidation in cells and tissues of central nervous system. J Neurochem 1999, 72:2531-2538.
27. Stirone C, Duckles SP, Krause DN, Procaccio V Estrogen increases mitochondrial efficiency and reduces oxidative stress in cerebral blood vessels. Mol Pharmacol 2005, 68:959-965.
28. Massafra C, Gioia D, DeFelice C, Piccolini E, Deleo V, Bonfazi B, et al. Effects of estrogens and androgens on erythrocyte and glutathione peroxidase activities during the menstrual cycle. J Endocrinol 2000, 167:447-520.
29. Lutoslawska G, Tkaczyk J, Panczenko-Kresowska B, Hubner-Wozniak E, Skierska E, Gajewski AK Plasma TBARS, blood GSH concentrations and erythrocytes antioxidant enzyme activities in regularly menstruating women with ovulatory and anovulatory menstrual cycle. Clin Chim Acta 2003, 331:159-163.
30. Rosenfeld R, Livne D, Nevo O, Dayan L, Milloul V, Lavi S, Jacob G Hormonal and volume dysregulation in women with premenstrual syndrome. Hypertension 2008, 51:1225-1230.
31. Bjôrn I, Sundstrôm-Poromaa I, Bixo M, Nyberg S, Bâckstrôm G, Bâckstrôm T Increase of estrogen dose deteriorates mood during progestin phase in sequential hormonal therapy. J Clin Endocrinol Metab 2003, 88:2026-2030.
32. Redei E, Freeman EW Daily plasma estradiol and progesterone levels over the menstrual cycle and their relation to premenstrual symptoms. Psychoneuroendocrinology 1995, 20:259-267.
33. Andréen L, Bixo M, Nyberg S, Sundstrôm-Poromaa I, Bâckstrôm T Progesterone effects during sequential hormone replacement therapy. Eur J Endocrinol 2003, 148:571-577.
34. Reed SC, Levin FR, Evans SM Changes in mood, cognitive performance and appetite in the late luteal and follicular phases of the menstrual cycle in women with and without PMDD (premenstrual dysphoric disorder). Horm Behav 2008, 54:185-193.
35. Taylor SE, Klein LC, Lewis BP, Gruenewald TC, Gurung RAR, Updegraff JA Biobehavioral responses to stress in females: tend- and -befriend not ight-or-flight. Psychol Rev 2000, 107:411-429.
36. Steiner M, Pearlstein T Premenstrual dysphoria and the serotonin system: pathophysiology and treatment. J Clin Psychiatry 2000, 61(suppl):17-21.
37. Reed SC, Levin FR, Evans SM Changes in mood, cognitive performance and appetite in the late luteal and follicular phases of the menstrual cycle in women with and without PMDD (premenstrual dysphoric disorder). Horm Behav 2008, 54:185-193.
38. Straneva PA, Maixner W, Light KC, Pedersen CA, Costello NL, Girdler SS Menstrual cycle, beta-endorphins, and pain sensitivity in premenstrual dysphoric disorder. Health Psychol 2002, 21:358-367.
39. Moosmann B, Behl C Secretory peptides hormones are biochemical antioxidants: structure activity relationship. Mol Pharmacol 2002, 61:260-268.